FierceBiotech

Atox Bio Announces Successful Completion of Phase 1 for AB103, a Novel Immunomodulator Being Developed for Severe Bacteria

NESS ZIONA, Israel--(BUSINESS WIRE)-- Atox Bio Inc. today announced that it successfully completed a phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections ...
Business Wire

FDA grants Fast Track designation to Atox Bio’s AB103 for the treatment of necrotizing soft tissue infections (NSTI)

NESS ZIONA, Israel--(BUSINESS WIRE)--Atox Bio, a clinical stage biotechnology company engaged in the development of novel immunemodulators for severe infections in critically ill patients, announced ...
Reuters

Atox Bio to seek funds by year-end for more trials

TEL AVIV, Sept 4 (Reuters) - Israeli biotechnology firm Atox Bio, developing a drug it hopes can treat severe infections such as those caused by flesh-eating bacteria and deadly viruses, expects to ...
Yahoo Finance

Telix Japan Signs MOU with ATOX to Use IRE ELiT 68Ge/68Ga-Generator for Phase I Study of Prostate Cancer Diagnostic Imaging

TOKYO, July 27, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Japan K.K., a wholly-owned subsidiary of Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce it has ...
ReadWrite

ATOX Esports CS2 team banned by ESIC over match-fixing scandal

When you buy through affiliate links in our content, we may earn a commission at no extra cost to you. Learn how our funding model works. By using this website you agree to our terms and conditions ...
FierceBiotech

Atox Bio Closes $23 Million Investment

NESS ZIONA, Israel--Atox Bio, developer of therapeutics for severe infections, today announced that it has raised up to $23 million in a Series E investment led by SR One with participation by ...
GEN

Fast-Track and Atox Score $575K Grant to Move Septic Shock Treatment into Clinic

Funding from a U.S.-Israeli fund will support advanced preclinical and Phase I testing. Fast-Track Drugs & Biologics and Atox Bio, a spin-out of the Hebrew University of Jerusalem, won a $575,000 ...
Yahoo

Atox Bio raises $23 million to fund flesh-eating bacteria treatment

TEL AVIV (Reuters) - Israel-based Atox Bio, a developer of therapeutics for severe infections, said on Thursday it has raised $23 million in an investment round led by SR One, the healthcare venture ...
GEN

Atox Bio Wins Potentially $24M BARDA Contract for Flesh-Eating Bacteria Treatment

The Biomedical Advanced Research and Development Authority (BARDA) awarded Hebrew University of Jerusalem spinout Atox Bio with a contract that could be worth up to $24 million to develop its lead ...
Business Insider

Atox Bio Awarded Next Milestone-based Option by BARDA to Support Continued Development of Reltecimod for Necrotizing Soft Tissue Infections

NESS ZIONA, Israel and CHAPEL HILL, North Carolina, Sept. 25, 2017 /PRNewswire/ -- Atox Bio today announced that it has been awarded the next option on a performance-based contract with the Biomedical ...
technologynetworks

Atox Bio Closes $23 Million Investment

Atox Bio has announced that it has raised up to $23 million in a Series E investment led by SR One with participation by Lundbeckfond Ventures and OrbiMed Israel. The funds will enable Atox Bio to ...